I'd be really interested to know what@otherperspective and other posters more knowledgeable than I think about whether this Aducanumab approval changes the approval prospects for our treatments. I wonder if the SP appreciation today is as a result of this with investors thinking this signals a new approach from the FDA.
- Does it suggest a shift in approach from the FDA or should it be viewed in isolation?
- Did its phase III trial miss primary end point? And was it approved on secondary endpoints?
- What about the black letter law approach to MOA in the FDA hearing re Ryoncil? Is that out the window too, or are we reading too much into a single decision by a big cumbersome and capricious agency?
- Forums
- ASX - By Stock
- MSB
- Alzheimer drug approved
Alzheimer drug approved, page-59
-
-
- There are more pages in this discussion • 185 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.15 |
Change
0.000(0.00%) |
Mkt cap ! $1.304B |
Open | High | Low | Value | Volume |
$1.15 | $1.17 | $1.13 | $3.335M | 2.908M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 3905 | $1.21 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.10 | 141 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
22 | 65299 | 1.150 |
12 | 82811 | 1.145 |
12 | 177739 | 1.140 |
11 | 173836 | 1.135 |
10 | 559289 | 1.130 |
Price($) | Vol. | No. |
---|---|---|
1.155 | 29440 | 11 |
1.160 | 143646 | 10 |
1.165 | 146296 | 9 |
1.170 | 135034 | 12 |
1.175 | 54294 | 4 |
Last trade - 15.59pm 22/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |